Heterogeneity of O-glycosylation in the hinge region of human IgA1
- PMID: 11399322
- DOI: 10.1016/s0161-5890(01)00019-0
Heterogeneity of O-glycosylation in the hinge region of human IgA1
Abstract
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry was applied to studies of the molecular heterogeneity of desialylated human IgA1 hinge region glycopeptides released with two IgA1 proteases. Typically, the hinge region of an alpha1 chain contains three to five O-linked glycan chains. Variants of the hinge region peptides released from IgA1(Kni) myeloma protein carrying 0, 1, 2, or 3 GalNAc residues were observed in the mass spectra as well as the nonglycosylated peptide. Variable numbers of Gal residues indicated additional heterogeneity in O-glycosylation of IgA1. In the hinge region preparation from normal human serum IgA1, glycopeptides carrying 2, 3, 4, or 5 GalNAc residues with variable numbers of Gal residues were detected. In conclusion, our new approach using the site-specific cleavage with two IgA1 proteases allowed precise and sensitive MALDI-TOF mass spectrometric analysis of O-glycosylation heterogeneity in IgA1 hinge region.
Similar articles
-
Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing.J Proteomics. 2013 Oct 30;92:299-312. doi: 10.1016/j.jprot.2013.07.013. Epub 2013 Jul 24. J Proteomics. 2013. PMID: 23891555 Free PMC article.
-
Estimation of the number of O-linked oligosaccharides per heavy chain of human serum IgA1 by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) analysis of the hinge glycopeptide.J Biochem. 1996 Aug;120(2):393-7. doi: 10.1093/oxfordjournals.jbchem.a021425. J Biochem. 1996. PMID: 8889826
-
Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry.J Biol Chem. 2005 May 13;280(19):19136-45. doi: 10.1074/jbc.M411368200. Epub 2005 Feb 22. J Biol Chem. 2005. PMID: 15728186
-
IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells.Contrib Nephrol. 2007;157:134-8. doi: 10.1159/000102455. Contrib Nephrol. 2007. PMID: 17495451 Review.
-
IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1.Contrib Nephrol. 2007;157:129-33. doi: 10.1159/000102454. Contrib Nephrol. 2007. PMID: 17495450 Review.
Cited by
-
Urinary CXCL1: a novel predictor of IgA nephropathy progression.PLoS One. 2015 Mar 27;10(3):e0119033. doi: 10.1371/journal.pone.0119033. eCollection 2015. PLoS One. 2015. PMID: 25816025 Free PMC article.
-
In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells.Results Immunol. 2012 Jan 1;2:166-172. doi: 10.1016/j.rinim.2012.08.002. Results Immunol. 2012. PMID: 24052934 Free PMC article.
-
Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individuals.Mol Cell Proteomics. 2014 Nov;13(11):3097-113. doi: 10.1074/mcp.M114.039693. Epub 2014 Jul 28. Mol Cell Proteomics. 2014. PMID: 25071157 Free PMC article.
-
Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV.MAbs. 2014;6(6):1585-97. doi: 10.4161/mabs.36336. MAbs. 2014. PMID: 25484063 Free PMC article.
-
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy.Bioengineering (Basel). 2017 May 8;4(2):42. doi: 10.3390/bioengineering4020042. Bioengineering (Basel). 2017. PMID: 28952521 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources